Who
Alejandra Carvajal
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, CytomX Therapeutics; SVP, Chief Legal Officer, Mersana Therapeutics; Chief Legal Officer, Momenta Pharmaceuticals; VP, General Counsel, Dare Bioscience.
In numbers
- Trades disclosed
- 121
- Buys
- 0
- Sells
- 23
- Bought
- $0
- Sold
- $1.5M
- Companies
- 4
- Companies where not an officer
- 0
- First trade
- 1 Dec 2015
- Last trade
- 3 Aug 2026
- Last filed
- 5 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Aug 2026filed 5 Aug 2026 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 3 Aug 2026filed 5 Aug 2026 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —450,000 at $0.00 | filing |
| 3 Aug 2026filed 5 Aug 2026 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —450,000 at $0.00 | filing |
| 3 Aug 2026filed 5 Aug 2026 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana TherapeuticsBiotechnology | SEC FORM 4 Code U | —3,131 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —100 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —717 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,500 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,166 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —3,047 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —6,702 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative | SEC FORM 4 Code D | —3,047 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative | SEC FORM 4 Code D | —6,702 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative | SEC FORM 4 Code D | —4,500 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative | SEC FORM 4 Code D | —1,800 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative | SEC FORM 4 Code D | —1,527 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative | SEC FORM 4 Code D | —4,922 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative | SEC FORM 4 Code D | —1,078 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative | SEC FORM 4 Code D | —7,921 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative | SEC FORM 4 Code D | —100 | filing |
News
No headline names them, or the companies they trade most, lately.